Introduction: The impact of selective surgical resection for patients with esophageal cancer treated with definitive chemoradiation has not been clearly evaluated long-term.
Introduction
Radiation Therapy Oncology Group (RTOG) trial RTOG 85-01 demonstrated long-term survival with a predominantly nonoperative approach for nonmetastatic squamous cell carcinoma of the esophagus treated with cisplatin, fluorocil (5-FU), and 50. 4 Gy of concurrent radiation. 1 Subsequent attempts by RTOG to decrease the high locoregional relapse rate (40%-60%) of this nonoperative approach with induction chemotherapy and higher doses of radiation therapy (intergroup trial 0122 and intergroup trial 0123) resulted only in increased toxicity without any improvement in survival or locoregional relapse (60%). 2, 3 NRG (National Surgical Adjuvant Breast and Bowel Project, Radiation Therapy Oncology Group, Gynecologic Oncology Group) Oncology RTOG 0246 was therefore put forward as an esophaguspreserving selective surgical strategy to address this high locoregional relapse rate with surgery for patients with a clinical incomplete response. Although encouraging, the preliminary results of NRG Oncology RTOG 0246 (1-year survival rate 71% [CI: 54-82]) did not achieve the target goal of a 1-year survival rate of 77.5%. 4 The long-term results of this organ-preserving selective surgical strategy are now the focus of this report.
Materials and Methods

Protocol Population
Patients were eligible for the trial if they had nonmetastatic squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction with less than 2 cm of gastric involvement. Adequate bone marrow, liver, and renal function and the ability to tolerate surgical resection with a Zubrod performance status of 0 or 1 were required for entry. Patients were also required to have greater than a cT1N0 tumor on endoscopic ultrasound (EUS) scan. Exclusion criteria included celiac adenopathy (>2 cm) or supraclavicular adenopathy unless biopsy-proven absence of cancer was obtained before study entry.
Pretreatment Assessment
All patients were assessed by a multidisciplinary team consisting of a medical oncologist, surgical oncologist, and radiation oncologist before study entry. Computed tomography (CT) of the chest and abdomen, endoscopy (esophagogastroduodenoscopy [EGD]), and EUS were required. Bronchoscopy was performed for tumors less than 25 cm from incisors. CT/positron emission tomography (PET) was optional but strongly encouraged. All institutions obtained institutional review board approval before patient recruitment, and all patients signed approved informed consent form before trial enrollment.
Therapy
Induction Chemotherapy. Induction chemotherapy consisted of two cycles of continuous 5-FU (650 mg/m 2 / d) and an intravenous 1-hour infusion cisplatin (15 mg/ m 2 /d) on days 1 to 5 and 29 to 33, as well as paclitaxel (200 mg/m 2 /d) as a 2-hour infusion on days 1 and 29. Pegylated granulocyte colony-stimulating factor (6 mg) was administered on days 6 and 34, or granulocyte colony-stimulating factor (300 or 480 mg) was administered on days 6 to 15 and 34 to 42.
Chemoradiotherapy. Chemoradiotherapy was begun upon completion of induction chemotherapy on day 58 of the protocol. The total radiotherapy dose of 50.4 Gy was delivered in 28 daily fractions (1.8 Gy per fraction) 5 d/wk. Simulation utilized CT, EGD, and esophagography to determine boundaries of the carcinoma. Threedimensional conformal radiotherapy was used, but intensity-modulated radiotherapy was not allowed. Borders of the field were as previously described. Concurrent outpatient chemotherapy consisted of 5-FU (300 mg/m 2 /d) as a continuous infusion for 5 d/wk during radiotherapy; cisplatin was administered at 15 mg/m 2 / d as a 1-hour infusion on days 1 to 5 of radiotherapy. Dose modifications (only radiation) were allowed as previously described. 4 
Assessment for Clin CR
Six to eight weeks after completion of chemoradiation, patients were assessed for clinical complete response (Clin CR) with EGD, EUS, CT of the chest and abdomen, and CT/PET (optional but highly encouraged). Patients were also evaluated by a multidisciplinary team of medical, surgical, and radiation oncologists. Clin CR was defined as no evidence of increased mass or metastases on CT of the chest and abdomen, negative biopsy result on repeat EGD, and resolution of fludeoxyglucose F 18 activity if a CT/PET scan was obtained. All patients with suspected residual disease in the esophagus and/or locoregional lymph nodes (clinical incomplete response [Clin Non-CR]) and no metastatic disease who were physiologically fit underwent selective esophageal resection of both the esophagus and locoregional lymph nodes at that time.
Patients who were thought to have a Clin CR were carefully monitored without surgical resection; the monitoring included a medical history and physical examination, serum chemistry profile, CT scan of the chest and abdomen, endoscopic biopsy, endoscopic ultrasound scan, and PET scan (optional but encouraged) and was performed every 3 months twice, every 6 months three times, and then yearly. During surveillance, selective esophageal resection of both the esophagus and locoregional lymph nodes was considered for patients who did not have systemic disease and were physiologically fit for surgery but in whom recurrent disease developed in the esophagus and/or locoregional lymph nodes.
Statistical Analysis
The primary end point of the study was 1-year overall survival (OS) for all patients eligible for analysis (those with biopsy-proven nonmetastatic resectable squamous cell or adenocarcinoma of esophagus or gastroesophageal junction with celiac adenopathy [<2 cm] and no supraclavicular adenopathy who were physiologically fit for surgery). Secondary end points included disease-free survival (failure included local, regional, and distant failure, as well as death due to any cause) and feasibility of a selective approach with induction chemotherapy, concurrent chemoradiation, and selective surgical resection. On the basis of a 1-year survival rate of 60% from the RTOG esophageal database, it was decided that a 1-year survival rate of 77.5% or better was needed for the trial to be deemed promising enough for study in a phase III protocol (hazard reduction w50% with a type I error of 0.05 and type II error of 0.20). When this figure was adjusted by 10% to account for patient ineligibility or loss, a total sample size of 42 patients was estimated to be required for this study. The data provided in this report were current as of May 15, 2014 . The outcome end points were calculated from date of trial registration. Time to distant failure was estimated by the cumulative incidence method. 5 Failure for OS was death as a result of any cause. OS rates were estimated univariately with the KaplanMeier method. 6 All analyses were performed using SAS STAT software (SAS Inc., Cary, NC).
Results
NRG Oncology RTOG 0246 opened on September 5, 2003 , and closed on March 17, 2006 , after accrual of a total of 43 patients. Two patients were ineligible for analysis because one patient never had bronchoscopy and the second patient had an unverifiable histologic type. The median follow-up time for the 12 patients still alive at the time of this analysis was 8.10 years (minimum to maximum 7.23-9.81 years). Pretreatment characteristics have been previously reported. 4 At the completion of definitive chemoradiation, 15 of 36 patients (42%) were classified as Clin CR and 21 of 36 patients (58%) were classified as Clin Non-CR by a multidisciplinary group of surgical, medical, and radiation oncologists. Most patients did not undergo CT-PET in their surveillance, making interpretation of the benefit of this modality for decision making of residual disease difficult. Clinical factors associated with treatment response are listed in Table 1 .
Long-Term Survival and Morbidity
As Figure 1 demonstrates, 41 patients were eligible for analysis. A total of four treatment-related deaths (grade 5) were noted (9.8%) 4 ; two patients died during induction chemotherapy (one died of pneumonia and one of multiorgan failure), one patient died after an operation (esophageal leak), and one patient died from pneumonitis (Supplementary Fig. 1) . Seventeen of these patients underwent selective esophagectomy for suspected local residual disease, with 5-and 7-year OS rates of 41.2% (95% CI: 18.6-62.6) and 35.3% (95% CI: 14.5-57.0). Survival was similar by histologic type (see Table 2 ). There was no statistically significant association with histologic and Clin CR status (see Table 1 ) after definitive chemoradiation.
Patterns of Failure
Twenty-one patients (57%) demonstrated locoregional relapse after definitive chemoradiation. Recurrent locoregional disease developed in three Clin CR patients during surveillance, and they underwent selective esophageal resection (5.3 to 14.9 months after completion of definitive chemoradiation). Eighteen Clin Non-CR patients had residual locoregional disease immediately after definitive chemoradiation (17 underwent surgical resection and all had residual local disease in their resected specimen; one patient was medically inoperable). The rate of distant failure for all patients at both 5 and 7 years was 31.7% (95% CI: 17.2-46.2) (Supplementary Fig. 2 ).
Discussion
NRG Oncology RTOG 0246 is attempting to determine in a population consisting predominantly of patients with adenocarcinoma whether selective surgical resection after definitive chemoradiation is feasible. The long-term results of this study (5-and 7-year survival) suggest that this strategy is not only feasible but may also confer benefit over definitive chemoradiation alone with prolonged follow-up. Only a minority of deaths in the Clin CR nonsurgical patients were due to disease progression, suggesting that observation may be reasonable for this subset of patients. The 5-and 7-year survival rates achieved in NRG Oncology RTOG 0246 appear greater than the 5-and 7-year survival rates of RTOG 85-01 (37% and 32%, respectively, versus 20% and 14%, respectively) 1, 4 and to those in recent definitive chemoradiation studies (INT 123, PRODIGES5/ACCORD17, and SCOPE1) with 3-year survival rates of 28%, 27%, and 28%, respectively, suggesting that the improved outcomes noted in NRG Oncology RTOG 0246 are not due solely to the more recent time period or improved staging of the current study. 4, 7, 8 Figure 1. NRG Oncology Radiation Therapy Oncology Group 0246 CONSORT diagram. chemo, chemotherapy; AE, adverse event; NOS, not otherwise specified; CR, complete response; CRT, chemoradiaion; Mets, metastases; adeno, adenocarcinoma; squamous, squamous cell carcinoma; GI, gastrointestinal.
Long-term distant failure is similar between NRG Oncology RTOG 0246 and RTOG 85-01, with a 7-year failure rate of 32%. 3, 4 The possibility therefore exists that the prolonged survival noted in NRG Oncology RTOG 0246 may be due to improved locoregional control achieved through improved chemoradiation strategies. NRG Oncology RTOG 0246 utilized chemotherapy before chemoradiation, and this strategy has been associated with a nonsignificant trend toward increased pathologic CR in a randomized phase II study. 9 The addition of taxanes to cisplatin and fluoruracil has also demonstrated high pathologic CR in several studies. 10 The use of selective surgery for Clin Non-CR patients may also have contributed to the improved long-term results of NRG Oncology RTOG 0246. Two randomized European studies comparing chemoradiation and surgery to definitive chemoradiation alone have been completed. These studies suggest that surgery does not benefit clinical responders to a large degree. In the Fondation Francaise de Cancerologie Digestive trial 9901, only clinical responders were randomized, and there was no benefit in the addition of surgery. 11 In the German study, all patients were randomized, but only the subset of clinical nonresponders appeared to benefit from the addition of surgery (3-year survival rate of 18% versus 9%). 12 In the German trial, clinical nonresponders in whom an R0 resection was able to be achieved were noted to have a 3-year survival rate of 32%. These observations suggest that selective surgical resection targeting clinical nonresponders may allow selective use of surgical resection for the group of patients most in need of locoregional control.
Another important difference between NRG Oncology RTOG 0246 and other definitive chemoradiation trials (RTOG 85-01, INT 123, SCOPE1) is the higher proportion of adenocarcinoma (73% versus 15%-25%). 1, 3, 4, 7, 8 Cooper et al. noted that shorter survival was associated with patients with adenocarcinoma than with patients with squamous cell carcinoma after definitive chemoradiation, with 5-year survival rates of 13% versus 21% noted in patients with squamous cell carcinoma. 1 The long-term results of NRG Oncology RTOG 0246 suggest that there is no difference between patients with adenocarcinoma and those with squamous cell cancer and that both can be approached in a selective fashion. As Table 1 demonstrates, histologic type does not appear associated with treatment response, and 5-and 7-year survival rates are similar between the groups (see Table 2 ). This is an important observation because an increasing proportion of patients in Western countries are presenting with adenocarcinoma of the esophagus or gastroesophageal junction. NRG Oncology RTOG 0246 utilized an esophaguspreserving strategy of selective esophageal resection. After definitive chemoradiation, a large portion of patients (57%) were classified as Clin Non-CR (see Fig. 1 ). More than 80% of those patients who were Clin Non-CR could be selectively resected with minimal morbidity at high-volume centers. All 17 patients who underwent an immediate operation for suspected residual disease demonstrated viable tumor in the resected specimen. Long-term survival of this group (Clin Non-CR surgical patients) was encouraging, with 5-and 7-year survival rates of 41% and 35%, respectively. In the Clin CR group (n ¼ 15), long-term survival was even better, with 5-and 7-year rates of 53% and 47% and only three patients required salvage surgery at a later time for recurrent disease (see Fig. 1 ). The benefits of an esophagus-preserving strategy include reduced short-term morbidity and mortality from surgery and possible reduced longterm consequences of esophageal resection, including reflux, dumping, and dysphagia. 12 Some authors have argued that salvage esophageal resection is associated with increased morbidity and therefore surgical resection should always be performed in a planned fashion. In this study, only three patients underwent salvage resection (esophageal resection for recurrent disease identified on follow-up) and there was no operative mortality or esophageal anastomotic leak noted. It is possible that salvage resection in populations with adenocarcinoma is associated with lower risk and that techniques have improved over time, reducing the risk of salvage resections. M. D. Anderson Cancer Center recently reported 65 patients with adenocarcinoma who underwent salvage resection with an operative mortality similar to that with planned esophagectomy (5% versus 3%), suggesting that selective surveillance and salvage can be accomplished with acceptable outcomes in the modern era when performed on populations with adenocarcinoma at a high-volume institution.
14 NRG Oncology RTOG 0246 demonstrates the feasibility and encouraging long-term survival achievable with an esophagus-preserving strategy of selective surgical resection after definitive chemoradiation. The question remains whether this strategy is appropriate for all patients with esophageal cancer, including populations with squamous cell cancer and adenocarcinoma. Table 3 suggests that the long-term survival in NRG Oncology RTOG 0246 is comparable to that in most trimodality studies, including CALGB 9781 and the study by Urba et al. 15, 16 Only the recently reported CROSS study with a 3-year survival rate of 60% with chemoradiation and surgery demonstrate significantly greater survival than this study at early time points. 17 In summary, NRG Oncology RTOG 0246 demonstrates the feasibility of and promising survival with an organpreserving selective surgical resection approach. At the present time, a selective approach appears warranted in high-risk patients, but the question of the optimal approach in good-risk populations is still debatable. In the future, selective surgical resection may be further enhanced by molecular markers, clinical factors, and noninvasive imaging modalities such as CT-PET to help delineate the patients benefiting from esophageal resection. 18, 19 February 2017 Selective Esophagectomy after Chemoradiation
